Robins A H, Lucke W, McFadyen M L, Wright J P
Postgrad Med J. 1984 May;60(703):353-5. doi: 10.1136/pgmj.60.703.353.
Depression and anxiety were measured during the course of a double-blind, placebo-controlled trial of the histamine H2-receptor antagonist, ranitidine (150 mg twice daily), in patients suffering from duodenal ulcer but free of systemic disease. There were 25 patients in the ranitidine group (mean age: 33.2 years) and 28 in the placebo group (mean age: 37.2 years). In both groups there was a highly significant and progressive decrease in depression and anxiety scores over the 4 weeks of treatment. There were no instances of mental confusion. In our group of otherwise physically healthy patients, ranitidine appeared to be free of neuropsychiatric complications.
在一项针对患有十二指肠溃疡但无全身性疾病的患者进行的组胺H2受体拮抗剂雷尼替丁（每日两次，每次150毫克）的双盲、安慰剂对照试验过程中，对抑郁和焦虑状况进行了测量。雷尼替丁组有25名患者（平均年龄：33.2岁），安慰剂组有28名患者（平均年龄：37.2岁）。在治疗的4周内，两组的抑郁和焦虑评分均出现了高度显著且逐渐下降的情况。没有出现精神错乱的病例。在我们这群身体健康的患者中，雷尼替丁似乎没有神经精神方面的并发症。
